Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States
posted on 2020-05-06, 08:53authored byJonathan K. Kish, Debanjana Chatterjee, Yin Wan, Hsing-Ting Yu, Djibril Liassou, Bruce A. Feinberg
The above summary slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).